Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin

American Journal of Health-System Pharmacy

Volumn 63, Issue 23, 2006, Pages 2357-2364

  Jumadilova, Zhanna ^a   Varadharajan, Sujata ^b   Girase, Prafulla ^c   Ollendorf, Daniel A ^c  

^a PFIZER INC   (United States)

^b IPSEN   (France)

^c PharMetrics

Author keywords

Bladder diseases; Costs; Drug comparisons; Economics; Outcomes; Oxybutynin; Parasympatholytic agents; Release; Sustained action medications; Tolterodine

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; OXYBUTYNIN; TOLTERODINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; COST OF ILLNESS; DEPRESSION; EVALUATION; FEMALE; FRACTURE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 33845217665     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060038     Document Type: Article

References (44)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61:37-49.
2. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20:327-36.
3. Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87:760-6. [Erratum, BJU Int. 2001; 88:807.]
4. Lapitan MC, Chye PL, for the Asia-Pacific Continence Advisory Board. The epidemiology of overactive bladder among females in Asia: a questionnaire survey. Int Urogynecol J Pelvic Floor Dysfunct. 2001; 12:226-31.
5. Moorthy P, Lapitan MC, Quek PL et al. Prevalence of overactive bladder in Asian men: an epidemiological survey. BJU Int. 2004; 93:528-31.
6. Temml C, Heidler S, Ponholzer A et al. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol. 2005; 48:622-7.
7. Hu TW, Wagner TH, Bentkover JD et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003; 61:1123-8.
8. Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001; 57:1044-50.
9. Stach-Lempinen B, Sintonin H, Kujansuu E. The relationship between clinical parameters and health-related quality of life as measured by the 15D in incontinent women before and after treatment. Acta Obstet Gynecol Scand. 2004; 83:983-8.
10. Van der Vaart CH, De Leeuw JR, Roovers JP et al. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int. 2002; 90:544-9.
11. Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy. 2005; 25:511-9.
12. Zorn BH, Montgomery H, Pieper K et al. Urinary continence and depression. J Urol. 1999; 162:82-4.
13. Stach-Lempinen B, Hakala A, Laippala P et al. Severe depression determines quality of life in urinary incontinent women. Neurourol Urodyn. 2003; 22:563-8.
14. Wagner TH, Hu TW, Bentkover J et al. Health-related consequences of overactive bladder. Am J Manag Care. 2002; 8(suppl 19):S598-607.
15. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000; 6(suppl 11):574-9.
16. Brown JS, Vittinghoff E, Wyman JF et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000; 48:721-5.
17. Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother. 2001; 2:1685-701.
18. Kershen RT, Hsieh M. Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine. Curr Urol Rep. 2004; 5:359-67.
19. Andersson KE. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol. 2004; 3:46-53.
20. Payne CK. Behavioral therapy for overactive bladder. Urology. 2000; 55(suppl 5A):3-6.
21. Horrocks S, Somerset M, Stoddart H et al. What prevents older people from seeking treatment for urinary incontinence? A qualitative exploration of barriers to the use of community continence services. Fam Pract. 2004; 21:689-96.
22. Shaw C, Tansey R, Jackson C et al. Barriers to help seeking in people with urinary symptoms. Fam Pract. 2001; 18:48-52.
23. Ashworth PD. The meaning of incontinence: a qualitative study of non-geriatric urinary incontinence sufferers. J Adv Nurs. 1993; 18:1415-23.
24. Abrams P, Cardozo L, Khoury S et al. Incontinence - management. In: Proceedings of the Third International Consultation on Incontinence. Plymouth, United Kingdom: Health Publications Ltd.; 2005:818-25.
25. Van Kerrebroeck P, Kreder K, Jonas U et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001; 57:414-21.
26. Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004; 172(5, pt. 1):1919-24.
27. Chapple C, Khullar V, Gabriel Z et al. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol. 2005; 48:5-26.
28. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004; 45:420-9.
29. Swift S, Garely A, Dimpfl T et al. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2003; 14:50-4.
30. Anderson RU, Mobley D, Blank B et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161:1809-12.
31. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol. 2004; 22:251-6.
32. Junemann KP, Halaska M, Rittstein T et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol. 2005; 48:478-82.
33. Kelleher CJ, Reese PR, Pleil AM et al. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care. 2002; 8(suppl 19):S608-15.
34. Khullar V, Hill S, Laval KU et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology. 2004; 64:269-75.
35. Homma Y, Paick JS, Lee JG et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. 2003; 92:741-7.
36. Abrams P, Freeman R, Anderstrom C et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998; 81:801-10.
37. Barkin J, Corcos J, Radomski S et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther. 2004; 26:1026-36.
38. Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003; 78:687-95.
39. Varadharajan S, Jumadilova Z, Girase P et al. Economic impact of extended-release tolterodine versus immediate-and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care. 2005; 11(suppl 4):S140-9.
40. Bureau of Labor Statistics. Consumer price indexes. www.bls.gov/cpi/home. htm (accessed 2004 Oct 31).
41. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17:2265-81.
42. Vigod SN, Stewart DE. Major depression in female urinary incontinence. Psychosomatics. 2006; 47:147-51.
43. Irwin DE, Milsom I, Kopp Z et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006; 97:96-100.
44. Shaya FT, Blume S, Gu A et al. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care. 2005; 11(suppl 4):S121-9.